Pfizer Inc. (NYSE:PFE) Shares Sold by Aviance Capital Partners LLC

Aviance Capital Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 28.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 99,695 shares of the biopharmaceutical company’s stock after selling 39,581 shares during the quarter. Aviance Capital Partners LLC’s holdings in Pfizer were worth $2,526,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Bessemer Group Inc. increased its position in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer in the first quarter valued at approximately $8,283,000. Alta Advisers Ltd increased its position in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 13,100 shares in the last quarter. WCM Investment Management LLC increased its position in shares of Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company’s stock valued at $3,176,000 after buying an additional 10,051 shares in the last quarter. Finally, Sage Mountain Advisors LLC increased its position in shares of Pfizer by 7.3% in the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 1,404 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PFE. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Leerink Partners lowered their price target on Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 30th. Wolfe Research lifted their price target on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, TD Cowen lowered their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.55.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.45 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business’s fifty day simple moving average is $23.67 and its 200-day simple moving average is $24.84. The firm has a market cap of $144.66 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 EPS. The company’s quarterly revenue was down 7.8% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.76%. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.